Kansas PKD Research and Translation Core Center - Administrative Core

堪萨斯 PKD 研究和翻译核心中心 - 行政核心

基本信息

批准号：
10686055
负责人：
JAMES P CALVET
金额：
$ 10.57万
依托单位：
UNIVERSITY OF KANSAS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-15 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10686055
关键词：
Abnormal Cell Advisory Committees Advocate Area Autosomal Dominant Polycystic Kidney Biochemistry Biocompatible Materials Biological Markers Biomedical Research Cancer Center Cell Proliferation Cell model Cellular biology Clinical Investigator Clinical Research Clinical Trials Collaborations Communication Communities Cyst Decision Making Development Disease Disease Progression Education Educational workshop Effectiveness Ensure Evaluation FDA approved Fluids and Secretions Funding Genetic Models Grant Growth Institution Kansas Malignant Neoplasms Mission National Institute of Diabetes and Digestive and Kidney Diseases Pathway interactions Patient-Focused Outcomes Patients Play Reagent Recording of previous events Research Research Methodology Research Personnel Research Project Grants Research Support Resource Sharing Resources Review Committee Rodent Model Role Scientist Services Signal Transduction Site Techniques Technology Testing Translational Research Translations Work biomarker discovery clinical development clinical translation drug testing falls improved innovation member novel patient oriented programs recruit summer student symposium therapeutic target tolvaptan

项目摘要

Project Summary - Administrative Core The mission of the Kansas PKD Research and Translation Core Center (RTCC) is to promote PKD research by providing essential reagents, biomaterials, and service to the PKD research community for the advancement of our understanding of disease mechanisms, the discovery of biomarkers and therapeutic targets and the development of clinical trials to improve patient outcomes. The mission of the Center is based on research at Kansas that discovered and characterized many of the key pathways now being considered for PKD therapy, and that ultimately led to the development of Tolvaptan as the first FDA approved therapy for ADPKD. The Kansas PKD RTCC has created three biomedical research cores to support the research programs of external core users in the PKD Research Consortium and the greater PKD research community. These cores are: Core 1. Biomarkers, Biomaterials, and Cellular Models (Darren Wallace, Director), Core 2. Rodent Models & Drug Testing (Pamela Tran and Stephen Parnell, Co-Directors), and Core 3. Clinical Research (Alan Yu, Director). The Administrative Core will be responsible for setting the overall scientific direction of the Kansas PKD Center, overseeing core activities, and for prioritizing the distribution of resources to each of the cores. The Administrative Core will also be responsible for organizing a variety of educational enrichment activities, including a Summer Student Enrichment Program, PKD research methods workshops, professional development sessions, Research Methods and Advanced Technologies Program, research seminars, retreats, patient- oriented activities, and will work with the Central Coordinating Site (CCS) on the annual symposium. The Administrative Core has an Internal Advisory Committee (IAC) comprised of the center directors and core directors and established KUMC scientists outside the PKD field who will bring their expertise to the committee, plus a representative from the PKD patient community to serve as a patient advocate. All PKD Core Center activities will be regularly reviewed and evaluated by the Internal Advisory Committee for communication to the CCS Steering Committee, the External Evaluation Panel (EEP), and NIDDK. The Administrative Core will support the recruitment of new investigators into the PKD field through various mechanisms including an innovative internal pilot grant program in partnership with the KU Cancer Center to support research projects exploring the relationship between PKD and cancer. Finally, the Administrative Core will work to promote strong interactions between the Kansas PKD Center and the institution by interfacing its activities with other programs, centers, and institutes at KUMC, and by integrating the biomedical research cores with existing institutional shared resource centers and biomedical cores; and will encourage open and frequent communication with the CCS and with the other national PKD RTCCs to maximize the benefits offered by our unique, high-value core services to the national PKD community.

项目概要 - 行政核心堪萨斯 PKD 研究和翻译核心中心 (RTCC) 的使命是促进 PKD 通过向 PKD 研究界提供必要的试剂、生物材料和服务来进行研究增进我们对疾病机制的理解、生物标志物和治疗靶点的发现以及开展临床试验以改善患者的治疗结果。该中心的使命是基于堪萨斯州的一项研究发现并描述了目前正在考虑用于 PKD 的许多关键途径疗法，并最终导致托伐普坦的发展，成为 FDA 批准的第一个 ADPKD 疗法。堪萨斯 PKD RTCC 创建了三个生物医学研究核心来支持以下项目的研究项目： PKD 研究联盟和更大的 PKD 研究社区中的外部核心用户。这些核心包括：核心 1. 生物标志物、生物材料和细胞模型（Darren Wallace，主任），核心 2. 啮齿动物模型与药物测试（Pamela Tran 和 Stephen Parnell，联合主任），以及核心 3. 临床研究（Alan Yu，导演）。行政核心将负责制定堪萨斯州的总体科学方向 PKD 中心，监督核心活动，并优先向每个核心分配资源。这行政核心还将负责组织各种教育丰富活动，包括暑期学生拓展计划、PKD 研究方法研讨会、专业发展会议、研究方法和先进技术计划、研究研讨会、务虚会、患者- 定向活动，并将与中央协调站（CCS）合作举办年度研讨会。这行政核心设有内部咨询委员会（IAC），由中心主任和核心人员组成 PKD 领域之外的董事和知名 KUMC 科学家将把他们的专业知识带给委员会，再加上来自 PKD 患者社区的代表作为患者倡导者。所有 PKD 核心中心内部咨询委员会将定期审查和评估活动，并与 CCS 指导委员会、外部评估小组 (EEP) 和 NIDDK。行政核心将支持通过各种机制，包括创新性的机制，招募新的调查员进入公钥簿领域与 KU 癌症中心合作的内部试点资助计划，支持探索以下领域的研究项目 PKD 与癌症之间的关系。最后，行政核心将致力于促进强有力的互动通过将堪萨斯 PKD 中心的活动与其他项目、中心和机构联系起来，在堪萨斯 PKD 中心和该机构之间建立联系。 KUMC 的研究所，并将生物医学研究核心与现有机构共享资源相整合中心和生物医学核心；并将鼓励与 CCS 和与与其他国家 PKD RTCC 合作，最大限度地利用我们独特的高价值核心服务为国家多囊肾社区。